View Clinical Trials Below

Clinical Trials for Breast Cancer Treatments

Since 1989, breast cancer death rates have been decreasing thanks to advancements in treatment and earlier detection. At Regional Cancer Care Associates, we’re proud to be pioneers in the improvement of breast cancer treatments through our clinical trials. If you’re interest in enrolling in a breast cancer clinical trial, call RCCA today at 201-669-4706.

What Are Clinical Trials?

Before a new drug, medical strategy or device can be approved, it first must be evaluated for human use. This research process is called a clinical trial. As scientific studies, clinical trials are methodically designed to follow strict scientific standards. At the end of each trial, the data is used to determine if the new medical therapy is a safe and effective method for improving patient outcomes.

Why Should I Enroll in a Clinical Trial?

If you’ve been diagnosed with breast cancer, a clinical trial can give you access to the latest advancements and innovations in treatment methods and medications. In turn, you’ll participate in a research process that may one day help improve the quality of life for thousands of women and men around the world.It’s important to note that clinical trials are one of the final stages of a careful research process that’s been developed and tested in laboratories for a significant amount of time before being offered to humans. For your safety, all clinical trials are closely monitored by an institutional review board and scientific experts.Before agreeing to enroll in a breast cancer clinical trial, RCCA specialists require informed consent. This means that you’ll receive in-depth information about the trial, including treatments being used, its purpose and possible risks and benefits, prior to enrollment. And as far as cost of care goes, you won’t need to pay a penny. The company sponsoring the clinical trial will cover the bill, making clinical trials an affordable option for those diagnosed with breast cancer.

Breast Cancer Clinical Trials at RCCA

Your wellness and safety is placed above all else at RCCA. That’s why our clinical trials start with a personalized plan. To learn if you’re a good candidate for a breast cancer clinical trial, schedule an appointment with an RCCA cancer care physician today.
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Read more
DIARRHEA PREVENTION AND PROPHYLAXIS WITH CROFELEMER IN HER2 POSITIVE BREAST CANCER PATIENTS RECEIVING TRASTUZUMAB, PERTUZUMAB, AND DOCETAXEL OR PACLITAXEL WITH OR WITHOUT CARBOPLATIN
DIARRHEA PREVENTION AND PROPHYLAXIS WITH CROFELEMER IN HER2 POSITIVE BREAST CANCER PATIENTS RECEIVING TRASTUZUMAB, PERTUZUMAB, AND DOCETAXEL OR PACLITAXEL WITH OR WITHOUT CARBOPLATIN

DIARRHEA PREVENTION AND PROPHYLAXIS WITH CROFELEMER IN HER2 POSITIVE BREAST CANCER PATIENTS RECEIVING TRASTUZUMAB, PERTUZUMAB, AND DOCETAXEL OR PACLITAXEL WITH OR WITHOUT CARBOPLATIN

Read more
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

Read more
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

Read more
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study

Read more
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases

Read more
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Read more
Gut Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
Gut Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Gut Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Read more
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low risk DCIS: A Phase III Prospective Randomized Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low risk DCIS: A Phase III Prospective Randomized Trial

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low risk DCIS: A Phase III Prospective Randomized Trial

Read more
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Read more